Government of Canada to host the Diversifying the Federal Supply Chain Summit
OTTAWA, ON, March 16, 2023 /CNW/ - Canada's Procurement Ombudsman will host the Diversifying the Federal Supply Chain Summit on April 4 and 5, 2023.
Are you an Indigenous or a Diverse Supplier Aiming To Do Business with the Federal Government?
Now in its fifth year, the Summit, that will be held nationwide, virtually via Zoom, is intended to help increase diversity in the federal supply chain. The Summit will feature public and private sector programs that help small businesses and businesses led by Indigenous Peoples, Black and racialized Canadians, women, 2SLGBTQI+ Canadians, persons with disabilities and other underrepresented groups obtain federal government contracts.
Date: April 4 and 5, 2023, beginning at 11:00 a.m. (EST) on day 1 and at 1:00 p.m. (EST) on day 2.
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data of its novel drug candidate...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with...
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today...
